FDA Puts Several Drugs On Its “Nice” List; EMA Decides One Is “Naughty”
Executive Summary
NPS Pharmaceuticals, GSK, Roche and Cangene receive early holiday gifts as FDA goes on an approval spree. But EMA bears more bad news for Merck’s Tredaptive.
You may also be interested in...
FDA Advisory Cmte. Loosens Statistical Significance Standard, Waves GSK’s Anthrax Drug Through
An additional animal study that Human Genome Sciences did after receiving a “complete response” letter from FDA showed clinical benefit for raxibacumab, but with a p-value higher than the standard maximum value of 0.05.
Gattex Review Shows FDA Approach On MedGuides Outside REMS
FDA said a Medication Guide need not be encompassed within NPS Pharma’s proposed Risk Evaluation and Mitigation Strategy for teduglutide due to the extensive interactions between short bowel syndrome patients and their health care providers and the inclusion of other patient-directed materials.
European Pharmacovigilance Update Still Causing Concern
The European pharma industry understands the need to tighten EU pharmacovigilance rules, but increased powers for a new advisory and assessment body could signal trouble ahead.